Efficacy of Topical Blockade of Interleukin-1 in Experimental Dry Eye Disease

DSpace/Manakin Repository

Efficacy of Topical Blockade of Interleukin-1 in Experimental Dry Eye Disease

Citable link to this page


Title: Efficacy of Topical Blockade of Interleukin-1 in Experimental Dry Eye Disease
Author: Okanobo, Andre; Chauhan, Sunil Kumar; Dastjerdi, Mohammad H.; Kodati, Shilpa; Dana, Reza

Note: Order does not necessarily reflect citation order of authors.

Citation: Okanobo, Andre, Sunil K. Chauhan, Mohammad H. Dastjerdi, Shilpa Kodati, and Reza Dana. 2012. “Efficacy of Topical Blockade of Interleukin-1 in Experimental Dry Eye Disease.” American Journal of Ophthalmology 154 (1) (July): 63–71. doi:10.1016/j.ajo.2012.01.034.
Full Text & Related Files:
Abstract: PURPOSE
To evaluate the therapeutic efficacy of topical IL-1Ra in the treatment of Dry Eye Disease (DED).

Laboratory Investigation.

DED was induced in C57BL/6 female mice through exposure to a desiccating environment within a controlled environment chamber. Topical formulations containing 5% IL-1Ra, 1% methylprednisolone, 0.05% cyclosporin A (CsA), and a vehicle control containing carboxymethylcellulose sodium (CMC) were applied following the induction of dry eye. Corneal fluorescein staining (CFS) was performed by a masked observer in the different treatment groups. Immunohistochemical studies were undertaken to enumerate corneal CD11b+ cells, as well as to evaluate corneal lymphangiogenesis. Real-time polymerase reaction was used to quantify the expression of IL-1β in the cornea.

A significant decrease in CFS was observed following topical treatment with 5% IL-1Ra (P<0.01), 1% methylprednisolone (P<0.01), and 0.05% CsA (P<0.03). Additionally, a significant decrease in the numbers of central corneal CD11b+ cells (P<0.05), corneal lymphatic growth (P<0.05), and corneal IL-1β expression (P<0.003), compared to vehicle treated, were only demonstrated following treatment with 5% IL-1Ra and 1% methylprednisolone, and were absent following CsA treatment.

Topical treatment with IL-1Ra is efficacious in ameliorating the clinical signs of the DED, as well as in reducing underlying inflammation.These effects are comparab le to treatment with topical methylprednisolone. Topical IL-1Ra may hold promise as a novel therapeutic strategy in the treatment of dry eye.
Published Version: 10.1016/j.ajo.2012.01.034
Other Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3378826/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:34428278
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search